This webcast is designed to provide an overview on advances in the treatment options for breast cancer. This webcast will present data of most promising emerging agents currently in development for the treatment of breast cancer and is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

This Webcast will discuss the use of pharmacologic strategies subsequent to ACS and PCI. Landmark trials that established how contemporary antiplatelet strategies are applied in this setting will be discussed in the context of the risk of suboptimal platelet inhibition. Best practices for transitioning patients from inpatient to outpatient care will be addressed, with a focus on adherence to guideline-recommended strategies.

This Rapid Research Review (R³) will address the most recent developments in current and emerging treatment options for patients with GBM. Research highlights from the 2011 Society of NeuroOncology (SNO) annual meeting will also be incorporated. Discussion topics will encompass a disease overview, the current standard of care, and emerging therapies for the treatment of newly diagnosed and recurrent GBM. Expert commentary will illustrate the clinical implications of emerging data and case studies will highlight effective integration of these agents and regimens into treatment planning.

The goals of osteoporosis treatment are to reduce bone loss, prevent fractures, control pain, and prevent disability. Despite attempts to increase awareness of the magnitude and consequences of osteoporosis and recommendations for screening and treatment from multiple groups, the disease remains under-detected and under-treated in the United States. There is also a need to examine the current evidence on treatment efficacy and outcomes for all treatment options for VCFs in order to advise patients on appropriate therapy for their individual situation.

The management of metastatic CRPC continues to evolve as new agents with unique mechanisms are available to patients and physicians. As these therapies start to be incorporated in practice, there may be some confusion on how to treat patients. How and when to use particular agents, especially with an already approved agent, and how to manage specific patients, such as, asymptomatic patient, are examples. Guidance on optimal sequencing and switching of antiandrogens, chemotherapy, and immunotherapy and appropriate patient selection criteria in patients with CRPC is needed. The goal of this educational activity is to further educate medical oncologists, urologists, radio oncologists and nurses about the current standard of care in CRPC with new agents, best practices and safety considerations.

This webcast is designed to provide an overview on advances in the treatment options for lung cancer and head & neck cancer. In addition to the adjuvant therapy and surgery, this webcast will present data of most promising emerging agents currently in development for the treatment of lung cancer and head & neck cancer. This webcast is designed to provide clinical decision-making strategies for integration of novel therapeutic options into clinical practice.

Targeted agents like those directed against the HER2 and vascular endothelial growth factor (VEGF) pathways (and their promise of better patient outcomes regarding safety, survival, and quality of life) can change the clinical course for many patients with metastatic breast cancer. Interpreting data and applying it to clinical practice, however, can be difficult for many oncologists and those practicing in smaller communities. The goal of this CME expert panel discussion is to provide a comprehensive review of targeted therapies in MBC with a focus on HER2-positive disease, identification, and its management with current agents, with combination treatments, and with those in development.

This webcast is designed to provide an overview on advances in the treatment options for lung cancer and head & neck cancer. In addition to the adjuvant therapy, this webcast will present data of most promising emerging agents currently in development for the treatment of lung cancer and head & neck cancer. This webcast is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

This educational activity will review the etiology of bacterial conjunctivitis, describe the symptoms and factors to consider when establishing the clinical diagnosis, discuss the effect of topical antibiotics on the disease course, and outline key points to communicate to patients and/or caregivers to optimize medical therapy.

This enewsletter is designed to provide an overview on advances in the treatment options for lung cancer. In addition to the adjuvant therapy, this enewsletter will present data of most promising emerging agents currently in development for the treatment of lung cancer. This enewsletter is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

In this online presentation, participants will learn about the most current criteria for MS diagnosis and new developments to be used in diagnostic imaging, prognostic indicators for current therapies, findings from long-term clinical trials, as well as the benefits and risks of new and emerging therapies.

This webcast is designed to focus on diagnosis and treatment of promising treatment options currently in development for lung cancer and head & neck cancer. This webcast is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

Parkinson's disease (PD) has traditionally been classified as a movement disorder as its cardinal symptoms include tremor, rigidity, slowed movement and postural instability. However the importance of psychiatric and other non-motor symptoms (NMS) in the detection of disease and their impact on quality of life has forced clinicians to envision PD as a complex disorder that requires careful and thorough evaluation throughout their patients' lifetimes. It is necessary to understand that NMS often present early in disease, and it is the worsening of these symptoms that may spur individuals to seek medical attention. With disease progression, these symptoms invariably become more debilitating and are a clinical challenge to control over the long run. In addition to dopaminergic therapy, patients may require additional pharmacologic agents to control symptoms, adding to their burden of cost and complexity as they seek to sustain quality of life.

This educational activity will review how to screen patients prone to inflammation-related complications post-cataract surgery, review the local ocular approaches to controlling cataract surgery-related inflammation, describe the local ocular approaches to controlling the inflammation of noninfectious uveitis, and discuss how to educate patients about the proper use of topical ophthalmic and anti-inflammatory agents.

"Informed Treatment Decisions in Multiple Sclerosis" revolves around unscripted audio comments, opinions, and best practice strategies from a variety of MS-related medical professionals. The project also involves MS patients via anonymous, audio-based interviews designed to gain subjective information about what patients like and dislike about the way healthcare providers explain the risks and benefits of various MS therapies to them. Patient interviews, ‘best practice' comments by participating physicians and nurses, and relevant clinical data (graphics, narration, and text) are woven into an on-line educational course.

Several important advances over the past two years have changed the landscape of non-small cell lung cancer (NSCLC) management. (1) Several protocols for maintenance therapies are showing promise in advanced disease; (2) Several development-stage novel agents targeting new lung cancer signaling pathways are advancing in clinical trials; (3) Molecular profiling tools are becoming more widely available in the community setting and more widely used to support treatment planning for targeted therapies.

Medical professionals who treat cancer patients need to understand these important advances in NSCLC management, assess their implications for patient care within their own practice, and use this information to optimize patient assessment, counseling and treatment.

This eTutorial Webcast will assess current and emerging methods that apply immune-based strategies to the treatment of castration-resistant prostate cancer. During this program, traditional management strategies for castration-resistant prostate cancer will be reviewed. The basic science that underlies the development of immunological strategies for prostate cancer will be explored, as well as clinical trials that have assessed these approaches in patients with these tumors.

This Expert Commentary will review how to integrate personalized targeted therapy into the treatment of patients with HCC, manage toxicities of anti-cancer agents used in HCC, learn and apply the different staging and scoring systems used in HCC, and how to develop a strategy to enhance the multi-disciplinary approach for the management of HCC.

This webcast is designed to focus on novel therapies on the horizon and their mechanism of action. This webcast provides clinical decision-making strategies for appropriate integration of novel therapeutic options in the treatment of cancer.

Participate in this complimentary, certified performance improvement (PI) CME initiative to discover practical strategies for improving osteoporosis care to optimize patient outcomes. Topics include identifying and assessing fracture risk, selecting risk-appropriate treatment strategies, and implementing and monitoring comprehensive nonpharmacologic measures. This activity is approved through the American Board of Internal Medicine's (ABIM) Approved Quality Improvement (AQI) Pathway and is eligible for 20 points towards the Self-Evaluation of Practice Performance requirement of Maintenance of Certification (MOC).

Participate in this complimentary, certified performance improvement (PI) CME initiative to improve your practice performance and diabetes patient outcomes. This PI activity provides guideline-based performance benchmarks across key areas in diabetes care along with tools and resources to help attain these benchmark goals. This activity is approved through the American Board of Internal Medicine's (ABIM) Approved Quality Improvement (AQI) Pathway and is eligible for 20 points towards the Self-Evaluation of Practice Performance requirement of Maintenance of Certification (MOC).

Assessment of current treatment of patients with schizophrenia support the need for continued educational initiatives for clinicians who manage patients with this disease. An important focus for such efforts is effective management of patients as they transition from inpatient management to outpatient care. Poor continuity at this critical time has been repeatedly shown to increase the risk for poor adherence to therapy, readmission to inpatient facilities, and poorer clinical outcomes. This program will seek to address the continuity of care for patients with schizophrenia as they transition from inpatient to outpatient care.

This Continuing Medical Education program will present current information about new perspectives in multiple sclerosis, including discussion on pathology, immunology, diagnosis and disease management, as well as treatment therapies, magnetic resonance imaging techniques and clinical outcomes.

This webcast is designed to provide an overview on advances in the treatment options for colorectal cancer. In addition to the adjuvant therapy and surgery, this webcast will present data of most promising emerging agents currently in development for the treatment of colorectal and non-colorectal gastrointestinal cancers. This webcast is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

This CME initiative is designed to educate healthcare providers involved in the management of patients with RA. The goal of this activity is to present the most practical and beneficial information on assessment, intervention, and cohesive, individualized management strategies. The educational format of "Rheumatoid Arthritis 2011" consists of problem-based learning for clinical decision making. This 1 hour CME webcast will be hosted by CME University, freeCME.com, and Powerpak.com. Level 3 and 4 outcomes measurements will be obtained utilizing pre- and post-test surveys to gauge changes in knowledge and competency. Level 5 performance changes will be assessed using follow-up case vignettes issued 4-6 weeks following the activity.

As the second leading cause of cancer deaths, colorectal cancer (CRC) remains a major health problem in the United States. Although up to 90% of these tumors are curable if treated at early stages, a significant number of patients are not diagnosed with CRC until it has metastasized. Clearly, the need for improved screening and early detection is critical. Additionally, there continues to be a need for improved strategies to manage patients with metastatic disease. In recent years, advances in our understanding of tumor biology have resulted in the development of targeted therapies and increased attention to the role of molecular markers. This has allowed practitioners to employ more individualized approaches in their treatment of patients with advanced CRC. This program will review the use of molecular markers, evaluate the treatment options available, and summarize the management of the most common treatment-related adverse events to advance the knowledge of health care providers caring for patients with metastatic colorectal cancer.

This webcast is designed to focus on etiology, pathogenesis and most promising treatment options currently in development for malignant melanoma. This activity is designed to provide clinical decision-making strategies for appropriate integration of novel therapeutic options into the treatment of melanoma.

Parkinson's disease (PD) has traditionally been classified as a movement disorder as its cardinal symptoms include tremor, rigidity, slowed movement and postural instability. However the importance of psychiatric and other non-motor symptoms (NMS) in the detection of disease and their impact on quality of life has forced clinicians to envision PD as a complex disorder that requires careful and thorough evaluation throughout their patients' lifetimes. It is necessary to understand that NMS often present early in disease, and it is the worsening of these symptoms that may spur individuals to seek medical attention. With disease progression, these symptoms invariably become more debilitating and are a clinical challenge to control over the long run. In addition to dopaminergic therapy, patients may require additional pharmacologic agents to control symptoms, adding to their burden of cost and complexity as they seek to sustain quality of life.

Using a real patient, a faculty educator will demonstrate a typical (and less than effective) patient visit. This "visit" will be assessed by our two physician faculty who will also engage in a discussion of the primary educational content: that older adults exhibit a higher risk of urinary incontinence and overactive bladder due to age, co-morbidities, and polypharmacy, yet often their symptoms go untreated because of ineffective provider-patient communication and the mistaken view that urinary problems are an inevitable burden of aging.

Physicians and health care professionals believe that urinary incontinence is an expected outcome of aging. As a patient transitions from middle age through to old age, the consequences of incontinence move from toilet mapping and quality of life to isolation, depression, and increased risk of falls. Physicians must juggle co-morbidities in the older patient and identify appropriate behavioral and pharmacotherapy to meet the patient's needs and expectations.

This educational activity will discuss how to apply available tools to screen and diagnose patients with or at risk for growth failure, how to identify patients who are candidates for a referral, and the management of patients who are candidates for hormonal therapy.

This education program provides expert reviews of current approaches to bypass therapy for inhibitor management in hemophilia A, including discussion of prophylaxis vs. on-demand treatment, recent clinical data on prophylactic bypass therapy, and new consensus recommendations for prophylactic therapy.

Presentation and case discussion by a leader in leukemia treatment addressing:

• Intensive therapy in older individuals with AML
• Less intensive therapeutic approaches for AML
• Therapies on the horizon for AML
• Case studies illustrating less intensive therapy in older individuals with AML

Three webcasts presented by leaders in lung cancer research and treatment will review recent advances and current practice on specific topics, and discuss best practice in the context of case presentations.

This case-based interactive program will summarize the current evidence in support of HER2 testing and the interpretation of currently used testing methods, review clinical trials that have assessed HER2-targeted strategies in adjuvant and metastatic treatment settings in patients with breast cancer, apply pivotal clinical trial results to the management of patients with HER2-positive breast cancer, and describe how health care provider/patient communication techniques can be integrated into the routine care of patients with breast cancer.

This Simulated Live Broadcast is a 1-hour presentation, led by 2 faculty speakers and 1 moderator, that incorporates didactic lectures with case-based presentations. At the conclusion of the first week of the broadcast, the initial broadcast participants will have the opportunity to submit a moderated question to the faculty via teleconference line.

Important recent advances in melanoma biology, immunotherapy and molecularly targeted therapies are driving changes in patient assessment and treatment, particularly in advanced disease. This program presents four CME webcasts based on presentations and discussion by national leaders in melanoma research and treatment who gathered to review and assess recent progress in June 2011. Each webcast is focused on one aspect of recent advances in the field, offers up to 1.0 - 1.5 AMA PRA Category 1 Credit™ and is presented by several faculty.

The activity will provide clinical decision-making tools based on integration of novel therapeutic options for multiple myeloma.

Recent breakthroughs in understanding the pathogenesis of retinal vein occlusion have led to the use of vascular endothelial growth factor inhibitors in ophthalmology along with steroids, laser treatment, and surgery. The goal of this continuing medical education activity is to review the recent developments in this field and discuss the efficacy and safety of treatment options in light of currently available treatments.

This activity is designed to provide clinical decision-making strategies for appropriate integration of novel therapeutic options into the treatment of prostate cancer.

The activity is designed to provide clinical decision-making tools based on recent advances in lung cancer therapy.

This webcast which is based on the content of a case-based satellite symposium that took place at AUA will assess current and emerging immune-based methods to manage castration-resistant prostate cancer. During this program, immunological mechanisms that have been investigated for their utility in the setting of prostate cancer will be explored. Clinical trial results will be discussed and assessed in the context of their impact on state-of-the-art care to manage these difficult-to-treat forms of prostate cancer.

Four webcasts presented by leaders in prostate cancer research and treatment will review recent advances and current practice on specific topics, and discuss best practice in the context of case presentations. Each activity offers up to 1.0 AMA PRA Category 1 Credit™.

The Validation Model^SM is a new four-part series that seeks to enhance communication between patients and their health care providers. Patients with hepatitis C virus (HCV) infection were surveyed twice throughout the series to obtain a better understanding of their perspective about their disease and treatment experience. This important survey information will enable health care professionals to address their patients' greatest concerns about their disease and ultimately lead to improved patient care.

Developments and the approval of novel agents in the field of metastatic CRPC, including new cytotoxic agents, immune-based therapies, circulating tumor markers, and targeted agents have given patients and physicians new hope for the future. The questions that remain are how and when to choose these novel agents for particular patient types. The goal of this educational activity is to inform uro-oncologists, medical oncologists, and urologists about the current standard of care in CRPC, recently approved agents, novel agents in development, new clinical data, and how to apply it to clinical practice where applicable.

Parkinson's disease (PD) has traditionally been classified as a movement disorder as its cardinal symptoms include tremor, rigidity, slowed movement and postural instability. However the importance of psychiatric and other non-motor symptoms (NMS) in the detection of disease and their impact on quality of life has forced clinicians to envision PD as a complex disorder that requires careful and thorough evaluation throughout their patients' lifetimes. It is necessary to understand that NMS often present early in disease, and it is the worsening of these symptoms that may spur individuals to seek medical attention. With disease progression, these symptoms invariably become more debilitating and are a clinical challenge to control over the long run. In addition to dopaminergic therapy, patients may require additional pharmacologic agents to control symptoms, adding to their burden of cost and complexity as they seek to sustain quality of life.

Four webcasts presented by leaders in prostate cancer research and treatment will review recent advances and current practice on specific topics, and discuss best practice in the context of case presentations. Each activity offers up to 1.0 AMA PRA Category 1 Credit™.

The ultimate goal of diabetes treatment is to optimize the overall health of the patient. There is an unmet need for healthcare providers to learn and apply diabetes management strategies to maximize patient adherence to treatment regimens. The critical role of glycemic control—to promote weight loss and mitigate cardiovascular risk factors for patients with type 2 diabetes—needs to be further emphasized.

Major depressive disorder is heterogeneous, with differences in both diagnosis and treatment recommendations depending on age, life stage, and unique patient factors. This Mixed Media activity explores the heterogeneity of major depressive disorder through a mix of interactive cases and faculty-led presentation.

This activity is intended to cover state of the art treatment options for breast cancer.

Using an interactive case-based format, this educational activity discusses the prevalence of male hypogonadism, comorbidities associated with the disease, and the role of testosterone replacement therapy, to help primary care physicians improve the diagnosis, management, and treatment of this condition, ultimately improving their patients' quality of life.

This activity will focus on evaluating male lower urinary tract symptoms for differential diagnosis of OAB versus BPH. The faculty has incorporated evidence based approaches for treatment and management of OAB and BPH, and will provide indications for when it is appropriate to refer to specialists.

Bringing Outcomes Into Focus: A Learner's Guide to Translating Theory Into Action

The Reflective Case-Study Outcomes Compendium will review the results of the aforementioned patient surveys, summarize the key concepts of other activities, and provide a detailed overview of the educational outcomes as measured by pre- and post-test data. This information creates the opportunity to assess where you stand against your peers in the aggregate and where this medical oncology specialty community sits as a whole.

Gray Matter Atrophy in Multiple Sclerosis presents current information about gray matter in multiple sclerosis including discussion on pathology, pathogenesis, cortical demyelination and atrophy, as well as MRI techniques and clinical outcomes.

The goal of this educational activity is to discuss the pathogenesis of dry eye and the role of inflammation in the development of the disease, outline strategies to diagnose dry eye and recognize patients at risk for the condition, describe the importance of early and aggressive treatment to optimize patient outcomes and prevent progression of dry eye, and review clinical trial data on the available treatment for dry eye disease.

This program will review current imaging techniques for diagnosing MS and monitoring patient response to therapy, as well as clinical trial data on current and emerging treatments. Additionally, the impact of MS on quality of life and steps that can be taken to improve quality of life for these patients will be addressed.

Enhancing Osteoporosis Management Using a Performance Improvement Approach is an integrated educational Performance Improvement activity which will allow all participants to access a variety of learning formats and tools to assess and improve those involved in the care of patients who are diagnosed with or are at risk for developing osteoporosis.

Primary Cares: A Performance Improvement Activity Designed to Improve the Diagnosis and Management of COPD and Asthma is an integrated educational Performance Improvement activity which will allow all participants to access a variety of learning formats and tools to assess and improve those involved in the care of patients who are diagnosed with asthma or chronic obstructive pulmonary disease (COPD).

This case-based program will utilize the current medical literature as a basis for clinical decision-making in managing this most difficult-to-treat setting for CRC. The program will focus particularly on trials that have assessed targeted approaches and molecular markers, while considering the advantages and disadvantages of particular strategies in the context of their predicted side effect profiles.

This educational activity will discuss the efficacy, management of adverse events, and breakthrough issues associated with protease inhibitor-based combination therapy. Patients' views regarding their HCV infection and treatment will be incorporated into the activity. This patient perspective will enhance communication between health care providers and patients.

This activity is intended to cover emerging treatment options for solid tumors such as lung cancer, breast cancer, colorectal and non-colorectal gastrointestinal cancers, ovarian cancer, prostate cancer, renal cell carcinoma, brain cancer; and hematological malignancies such as lymphoma, leukemia and multiple myeloma.

This educational activity will provide the attendee with an overview of the current clinical trial data on NSCLC while highlighting diagnostic tools, current first- and second-line approaches to manage advanced disease, and developments in maintenance therapy. Finally, strategies to individualize therapy will be reviewed.

This program has been developed to provide the education needed to change the knowledge, skill, or attitude of the participant and assist in effectively closing identified practice gaps that will translate into better quality care for patients.

Breast cancer represents a heterogeneous array of different disease subtypes that have unique molecular phenotypes and distinct clinical features. Despite advances in the treatment of early-stage breast cancer, approximately one third of patients will eventually develop metastatic breast cancer (MBC). The increased understanding of the biology of breast cancer has led to the classification of tumors based upon their molecular features and the development and use of targeted therapies for the treatment of both early and metastatic cancer. Targeted agents and their promise of better patient outcomes with respect to safety, survival, and quality of life may change the clinical course for many MBC patients.

The goal of this activity is for primary care physicians and psychiatrists to increase recognition and diagnosis of adult ADHD and to disseminate recent findings regarding the effects of treatment in this population.

This case-based program will evaluate current and emerging methods to optimize CRC management in advanced disease. In particular, individualized treatment considerations will be discussed in the context of patients with potentially resectable liver metastases. The discussion will include surgical and neoadjuvant considerations and will apply current evidence to determine potential chemotherapeutic and targeted treatment options for these and other patients with advanced disease.

The activity will provide clinical decision-making tools based on novel targeted therapy option for various malignancies.